Dr. Ariel David Szvalb, MD

Dr. Szvalb practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Szvalb's NPI, 1548554033, was assigned on June 2, 2011. Dr. Szvalb holds Texas license Q0705.

Dr. Szvalb's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Szvalb's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Szvalb practices. Vendor and product names are available with a free account.

Infectious disease is Dr. Szvalb's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dr. Szvalb is licensed in Texas.

CMS data shows 280 Medicare services from Dr. Szvalb across 6 procedure codes in 2024, for 226 Medicare patients. Medicare paid $30,548 for them.

CMS counts 226 Medicare patients who saw Dr. Szvalb in 2024. The largest group is 65 to 74, with 118 patients. 75% of them have high blood pressure, and 72% have high cholesterol. 9% are also on Medicaid. Their average risk score is 3.40, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Szvalb's median patient age at 67, with 51% women.

In 2024, Dr. Szvalb wrote 190 Medicare Part D claims for 37 patients. 79% of them were for generic drugs. CMS names the drug for 72 of them, across 4 drugs with 11 or more claims each, at $57,261 in total drug cost. In 2023, CMS named 90 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Szvalb for performance year 2024, reported as part of a group. Dr. Szvalb accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Szvalb as offering telehealth.

Dmand AI links 14 papers to Dr. Szvalb, published from 2013 to 2022. 2022 was the busiest year, with 3. The most frequent topics are Anti-Bacterial Agents, Immunocompromised Host and Tomography, X-Ray Computed. Dr. Szvalb has published most often in Antimicrob Agents Chemother. Dr. Szvalb's most frequent co-authors are George Michael Viola, MD, MPH, Alexandre Elias Malek, MD and Dimitrios P. Kontoyiannis, MD.

CMS Open Payments shows 2 general payments to Dr. Szvalb from 2 drug and device companies from 2016 to 2018. Education make up the largest share, 79% of the total. Astellas Pharma US Inc paid the most, $70.